百济神州方面明确，吴晓滨博士职务不变，仍担任公司总裁兼首席运营官。这意味着百济神州成为医药 行业首家设立"双总裁"职位的企业。 21世纪经济报道记者 季媛媛 韩利明 值得注意的是，今年8月百济神州曾有重大人事变动，原武田制药全球高级副总裁、武田中国总裁单国 洪加入，出任大中华区、中亚和南亚区域总经理，向吴晓滨汇报。 12月19日，百济神州发布人事公告，核心管理团队迎来重大调整：公司全球研发负责人汪来博士出任总 裁，仍兼任全球研发负责人，全面统筹研发、业务拓展及业务联盟关系管理等核心职能。 针对此次变动后相关疑问，百济神州向21世纪经济报道记者回应：单国洪将继续向吴晓滨汇报；关于吴 晓滨辞任的不实信息后续将澄清，"吴晓滨为核心管理人员，若有新变动将及时披露。" ...

CHESHIRE, England, Dec. 19, 2025 /PRNewswire/ -- A leading sports physiotherapist has criticised the Premier League and English Football League (EFL) for 'prioritising profit over players' by continuing to turn a blind eye to the effects of a squeezed Christmas fixture list, which he says is jeopardising players' health and wellbeing. The Real Injury Time report, which is based on a research analysis by Dr Sean Williams, a leading academic in sports injury prevention from the University of Bath, and expert ...

Core Viewpoint - The Schwab U.S. Dividend Equity ETF is highlighted as a strong investment option for income- and value-seeking investors, especially in a potentially volatile stock market environment in 2026 [12][19]. Market Overview - The stock market has shown significant gains year-to-date, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite increasing by 13%, 14%, and 18% respectively as of December 17 [1]. - The current stock market is considered the second priciest in history, with concerns about sustainability as it approaches 2026 [2]. Valuation Metrics - The S&P 500's Shiller P/E Ratio, a key valuation metric, is currently at 39.59, which is 129% above its 155-year average of 17.32 [8]. - Historically, when the Shiller P/E has exceeded 30, it has been followed by significant declines in major indices [9][10]. ETF Performance and Strategy - The Schwab U.S. Dividend Equity ETF aims to mirror the total returns of the Dow Jones U.S. Dividend 100 Index and includes 103 established companies [14]. - The ETF offers a yield of approximately 3.8%, significantly higher than the S&P 500's yield of 1.12% [17]. - The average trailing 12-month P/E ratio for the companies in the Schwab U.S. Dividend Equity ETF is 17.18, compared to the S&P 500's 25.63 [18]. Investment Characteristics - The ETF is characterized by low management fees, with a net expense ratio of 0.06%, making it cost-effective for investors [17]. - The focus on high-quality dividend stocks has historically provided better returns and lower volatility compared to non-dividend payers [13].

ST人福12月19日公告，公司全资子公司湖北生物医药产业技术研究院有限公司收到国家药品监督管理 局核准签发的HW252001片的《药物临床试验批准通知书》，同意开展用于特发性肺纤维化适应症的临 床试验。 HW252001 片拟用于特发性肺纤维化的治疗，是一款口服的小分子新药。 ...

Not every stock needs a flashy growth story to outperform. Sometimes, the biggest winners are the companies that simply keep executing, quarter after quarter, year after year- it’s all about consistency. In 2025, a handful of quiet standouts are doing precisely that, delivering substantial year-to-date gains while continuing to reward investors with reliable income. These are businesses with deep moats, disciplined management teams, and a proven ability to thrive across market cycles. More News from Bar ...

Core Insights - Global diversification is increasingly important for Indian investors as market cycles do not align across geographies, allowing for risk balancing and reduced portfolio volatility [1][16] - Investment flows into overseas equities have significantly increased, with a rise from USD 152 million in August to USD 279 million in September, and FY25 recording the highest annual overseas investment figure at USD 1.7 billion [2][4] Investment Trends - Indian investors are motivated to invest in US equities to access global themes, particularly in technology and artificial intelligence, which are not easily available in domestic markets [6][19] - The US stock market has shown resilience and growth, with US equities rising nearly 15% in 2025, outperforming the Nifty 50, which is up around 10% [18] Investment Mechanisms - Indian investors can gain exposure to US equities through direct investment in US stocks or indirect investment via mutual funds or ETFs [7][19] - The Reserve Bank of India's Liberalised Remittance Scheme (LRS) allows residents to invest up to $250,000 per financial year in foreign assets, enhancing accessibility to global investing [8][19] Platforms and Accessibility - Platforms like Appreciate simplify the process of investing in US stocks, making it more intuitive for Indian investors [12][19] - The Appreciate App enables investors to start their global investing journey with minimal steps, promoting ease of access to US markets [12][19] Long-Term Performance - US-listed companies are at the forefront of innovation in sectors such as AI, biotechnology, and renewable energy, providing opportunities for Indian investors to participate in global growth [13][19] - Historical performance of indices like the S&P 500 and NASDAQ has shown consistent outperformance, adding to the appeal of US equities for long-term investors [14]

Core Insights - MEDIPOST has secured an $8 million upfront payment for the joint commercialization of its stem cell therapy CARTISTEM in Japan, targeting knee osteoarthritis [1][2] - The partnership with Teikoku Seiyaku Co., Ltd. includes exclusive sales, distribution, and promotion rights for CARTISTEM in Japan, while MEDIPOST retains manufacturing rights [2][3] - CARTISTEM has been administered to over 35,000 patients since its regulatory approval in South Korea in 2012 and is designed to regenerate cartilage in knee osteoarthritis patients [4] Company Overview - MEDIPOST, founded in 2000, is a global stem cell therapy company with capabilities in discovery research, clinical development, and cell and gene therapy contract development and manufacturing [5] - Teikoku Seiyaku, established in 1848, focuses on transdermal drug delivery technology and has a mission to alleviate pain, with ongoing efforts in the orthopedic sector [6][7] Market Strategy - Teikoku Seiyaku plans to utilize its extensive orthopedic hospital and clinic network to promote CARTISTEM, aiming to address unmet medical needs in knee osteoarthritis treatment in Japan [3][6] - The company is expanding its medical representative division to enhance the promotion of CARTISTEM ahead of its approval [3]

The stocks listed here trade at forward earnings multiples of less than 18.Valuations for many stocks are sky-high, and that can make now an unappealing time to invest in the stock market. However, there are still some great value buys that don't involve taking on a lot of risk or investing in unknown companies.Three of the best bargains you can buy today come from the healthcare sector. AstraZeneca (AZN +0.83%), CVS Health (CVS 0.13%), and Pfizer (PFE +0.04%) are all trading at incredibly low valuations wi ...

Core Insights - UnitedHealth Group and Eli Lilly are two leading healthcare companies, with UnitedHealth providing insurance and care services, while Eli Lilly is a major pharmaceutical player valued at $1 trillion [1] UnitedHealth Group - UnitedHealth Group has experienced a significant decline of nearly 35% since January 2025, primarily due to the removal of its insurance CEO and subsequent investigations into fraud and misconduct related to billing practices [2][4] - The company is facing unexpectedly high costs in its Medicare programs, which have negatively impacted earnings this year [4] - Management is responding by raising premiums and potentially withdrawing from certain markets, anticipating a loss of up to 1 million members from its Medicare Advantage plans, but expects these changes to enhance profitability in the long run [5] Eli Lilly - Eli Lilly's stock has surged nearly 35% in 2025, driven by its strong position in the growing market for anti-obesity drugs, with sales projected to increase from $15 billion last year to $150 billion over the next decade [2][6] - The company has achieved impressive revenue growth, reporting a 54% year-over-year increase in the third quarter [7] - Eli Lilly's pipeline includes promising anti-obesity drugs currently in phase 3 clinical trials, which could contribute to substantial growth over the next five to ten years [7]

Core Viewpoint - The company experienced a significant drop in stock price after discontinuing the development of a drug for chronic sinusitis, which failed to meet trial endpoints, despite a year-to-date increase of 141% and a market cap exceeding $35 billion [1][2]. Group 1: Drug Development and Market Impact - The discontinued drug was expected to generate sales of approximately $3 to $5 billion, with some estimates as high as $5 billion [3][4]. - The company still holds optimism for another drug, Brenzo, which is projected to achieve close to $10 billion in sales despite the recent setback [7]. - The probability of success for the next indication, a rare skin disease, is considered low, below 30% [6]. Group 2: Acquisition and Future Prospects - The recent acquisition of an antibody was seen as an attempt to bolster the pipeline, although it raised questions due to the timing of the announcement [8][9]. - Analysts suggest that the current stock price pullback to $165 presents a potential buying opportunity, with models indicating that the valuation is not excessive [10]. - Future growth is anticipated to be more modest, with expectations of a 20% to 30% increase rather than the previous year's 140% [11].